Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$22.00 USD
-0.03 (-0.14%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $21.99 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SAVA 22.00 -0.03(-0.14%)
Will SAVA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SAVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SAVA
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
Brian's Big Idea on Low Priced Stocks
SAVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cassava (SAVA) Up on Progress With Alzheimers Disease Study
Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
Other News for SAVA
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Analysts Offer Insights on Healthcare Companies: Aroa Biosurgery Ltd (AU:ARX), Cassava Sciences (SAVA) and Amplifon S.p.A. (GB:0N61)
Cassava receives patent allowance for Alzheimer's disease assay
Cassava Sciences call volume above normal and directionally bullish
Peering Into Cassava Sciences's Recent Short Interest